US pharma giant Pfizer (NYSE: PFE) shared some sad clinical trial news Tuesday.
The company disclosed that a boy taking part in the Phase II DAYLIGHT study for Duchenne muscular dystrophy (DMD) had died suddenly.
"The patient received the investigational gene therapy, fordadistrogene movaparvovec, in early 2023"This study is evaluating the safety and dystrophin expression of fordadistrogene movaparvovec, Pfizer’s gene therapy candidate for DMD, in boys who are two and three years old.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze